B. Riley Securities Maintains Buy on Altimmune, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Mayank Mamtani maintains a Buy rating on Altimmune (NASDAQ:ALT) but has lowered the price target from $15 to $8.
November 09, 2023 | 8:38 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Altimmune's price target has been lowered from $15 to $8 by B. Riley Securities, though the Buy rating is maintained.
The lowering of the price target by B. Riley Securities indicates a potential decrease in the stock's value. However, the maintained Buy rating suggests that the analyst still sees potential in the company. This could lead to short-term negative impact on the stock price, but potential long-term gains.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100